

**HSHS St. Vincent Hospital Regional Cancer Center –Adult Active Study List**

| Protocol             | Sponsor  | NCT Number  | Disease Site                           | Title                                                                                                                                                                                                     |
|----------------------|----------|-------------|----------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S1314                | SWOG-L   | NCT02177695 | Bladder                                | A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer                                                            |
| NHLBI-MDS            | ECOG-A   | NCT02775383 | Blood Disorders-Other                  | The National Myelodysplastic Syndromes (MDS) Study                                                                                                                                                        |
| PNH Registry M07-001 | DRUG CO  | NCT01374360 | Blood Disorders-Other                  | PNH Registry                                                                                                                                                                                              |
| A071102              | ALLIANCE | NCT02152982 | Brain                                  | A Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter Hypermethylation                                     |
| A221101              | ALLIANCE | NCT01781468 | Brain                                  | A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients with High Grade Glioma                                               |
| A221102              | ALLIANCE | NCT01573442 | Breast- Miscellaneous                  | Randomized Double-Blind Placebo Controlled Study of Testosterone in the Adjuvant Treatment of Postmenopausal Women with Aromatase Inhibitor Induced Arthralgias                                           |
| SC-1603              | ACCRU    | NCT02961790 | Breast- Miscellaneous                  | A Phase III, Double-Blind, Controlled Trial of Oxybutynin in the Management of Hot Flashes                                                                                                                |
| SCUSF 1102           | SCUSF    | NCT01789684 | Breast- Miscellaneous                  | A Cluster Randomized Controlled Trial Comparing Interventions to Enhance Utilization of Genetics Services Among Breast Cancer Patients                                                                    |
| WF 97116             | WAKE     | NCT02822573 | Breast- Miscellaneous                  | A Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors with Cognitive Impairment                                                             |
| BR002                | NRG      | NCT02364557 | Breast-Advanced (Metastatic/Recurrent) | A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer                                  |
| E2112                | ECOG     | NCT02115282 | Breast-Advanced (Metastatic/Recurrent) | A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer                                                               |
| R1119                | RTOG     | NCT01622868 | Breast-Advanced (Metastatic/Recurrent) | Phase II Randomized Study of Whole Brain Radiotherapy in Combination With Concurrent Lapatinib in Patients With Brain Metastasis From HER2-Positive Breast Cancer: A Collaborative Study of RTOG and KROG |

**HSHS St. Vincent Hospital Regional Cancer Center –Adult Active Study List**

| Protocol  | Sponsor  | NCT Number  | Disease Site                           | Title                                                                                                                                                                                                                                                                                                                                                               |
|-----------|----------|-------------|----------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| RU0112011 | ACCRU    | NCT02037529 | Breast-Advanced (Metastatic/Recurrent) | A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer                                                                                                                                                                                                  |
| S1416     | SWOG-L   | NCT02595905 | Breast-Advanced (Metastatic/Recurrent) | Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer                                                                                                                                                                             |
| A011202   | ALLIANCE | NCT01901094 | Breast-Early Stage (Adjuvant)          | A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy                                                                                                                                                       |
| A011401   | ALLIANCE | NCT02750826 | Breast-Early Stage (Adjuvant)          | Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer                                                                                                                                                                                                                          |
| A011502   | ALLIANCE | NCT02927249 | Breast-Early Stage (Adjuvant)          | A randomized phase III double blinded placebo controlled trial of aspirin as adjuvant therapy for node-positive HER2 negative breast cancer: The ABC trial                                                                                                                                                                                                          |
| B-51      | NSABP    | NCT01872975 | Breast-Early Stage (Adjuvant)          | A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy                                                              |
| B-55      | NSABP    | NCT02032823 | Breast-Early Stage (Adjuvant)          | A Randomized, Double-blind, Parallel group, Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy |
| BR003     | NRG      | NCT02488967 | Breast-Early Stage (Adjuvant)          | A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple Negative Invasive Breast Cancer                                                                                                                          |

**HSHS St. Vincent Hospital Regional Cancer Center –Adult Active Study List**

| Protocol       | Sponsor | NCT Number    | Disease Site                  | Title                                                                                                                                                                                                                                                                                                      |
|----------------|---------|---------------|-------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| E1Z11          | ECOG    | NCT01824836   | Breast-Early Stage (Adjuvant) | A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)                                                                                                                                                                                                      |
| EA1131         | ECOG-A  | NCT02445391   | Breast-Early Stage (Adjuvant) | A Randomized Phase III Post-Operative Trial of PlatinumBased Chemotherapy Vs. Capecitabine in Patients withResidual Triple-Negative Basal-Like Breast Cancerfollowing Neoadjuvant Chemotherapy                                                                                                             |
| PrE0109/AFT-05 | PrECOG  | NCT02513394   | Breast-Early Stage (Adjuvant) | PALLAS: PALbociclib CoLLaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer |
| S1207          | SWOG-L  | NCT01674140   | Breast-Early Stage (Adjuvant) | Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer.e3 Breast Cancer Study- evaluating everolimus with endocrine therapy.        |
| DCP-001        | DCP     | Not Available | Cancer Control-Other          | Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)                                                                                                                                                                               |
| N0392          | NCCTG   |               | Cancer Control-Other          | Assessment of Patient Satisfaction with Participation in Phase II/III NCCTG Clinical Trials                                                                                                                                                                                                                |
| URCC 14040     | URCC    | NCT02613364   | Cancer Control-Other          | A Randomized Clinical Trial Comparing the Effectiveness of Yoga, Survivorship Health Education, and Cognitive Behavioral Therapy for Treating Insomnia in Cancer Survivors                                                                                                                                 |
| URCC13059      | URCC    | NCT02054741   | Cancer Control-Other          | A Geriatric Assessment Intervention for Patients Aged 70 and Over Receiving Chemotherapy or Similar Agents for Advanced Cancer: Reducing Toxicity in Older Adults                                                                                                                                          |
| 0724           | RTOG    | NCT00980954   | Cervical                      | Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy                                                                                          |

**HSHS St. Vincent Hospital Regional Cancer Center –Adult Active Study List**

| Protocol | Sponsor  | NCT Number  | Disease Site                              | Title                                                                                                                                                                                                                                                                                           |
|----------|----------|-------------|-------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| G0263    | GOG      | NCT01101451 | Cervical                                  | Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy                                                                                          |
| C-13     | NSABP-F  | NCT02664077 | Colon                                     | A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients with Stage III Colon Cancer (ARGO)                                                                                                                            |
| GLNE010  | ALLIANCE | NCT01511653 | Colon and Rectal                          | Validation and Comparison of Biomarkers for the Early Detection of Colorectal Adenocarcinoma                                                                                                                                                                                                    |
| MPR-1    | NSABP-F  | NCT01793805 | Colon and Rectal                          | NSABP Patient Registry and Biospecimen Profiling Repository                                                                                                                                                                                                                                     |
| S0820    | SWOG-L   | NCT01349881 | Colon and Rectal                          | A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES) |
| 0920     | RTOG     | NCT00956007 | Head and Neck                             | A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer                                                                                                                                                                    |
| R1008    | RTOG     | NCT01220583 | Head and Neck                             | A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors                                                                                                                            |
| R1216    | RTOG     | NCT01810913 | Head and Neck                             | Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck                                                                                |
| E1910    | ECOG     | NCT02003222 | Leukemia-Acute Lymphocytic Leukemia (ALL) | A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults                                                                                                                                                              |

**HSHS St. Vincent Hospital Regional Cancer Center –Adult Active Study List**

| Protocol         | Sponsor  | NCT Number  | Disease Site                                | Title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|------------------|----------|-------------|---------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S1318            | SWOG-L   | NCT02143414 | Leukemia-Acute Lymphocytic Leukemia (ALL)   | A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients $\geq$ 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517), Prednisone and Blinatumomab for Patients $\geq$ 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Philadelphia-Chromosome Positive (+) ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) with Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF) |
| E2906            | ECOG     | NCT01041703 | Leukemia-Acute Myelogenous Leukemia (AML)   | Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age > 60 Years)                                                                                                                                                                                                                                                                                                                                                     |
| MDS/AML Registry | DRUG CO  | NCT01688011 | Leukemia-Acute Myelogenous Leukemia (AML)   | The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| PCYC-1134M-CA    | DRUG CO  | NCT02582879 | Leukemia-Chronic Lymphocytic Leukemia (CLL) | informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| A081105          | ALLIANCE | NCT02193282 | Lung- Non-Small Cell Lung Cancer            | Randomized Study of Erlotinib in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| A151216          | ALLIANCE | NCT02194738 | Lung- Non-Small Cell Lung Cancer            | Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| E4512            | ECOG-A   | NCT02201992 | Lung- Non-Small Cell Lung Cancer            | A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| EA5142           | ECOG-A   | NCT02595944 | Lung- Non-Small Cell Lung Cancer            | Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) – A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

**HSHS St. Vincent Hospital Regional Cancer Center –Adult Active Study List**

| Protocol          | Sponsor  | NCT Number   | Disease Site                     | Title                                                                                                                                                                                                                                                                                               |
|-------------------|----------|--------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Merck MK-3475-407 | DRUG CO  | NCT02775435  | Lung- Non-Small Cell Lung Cancer | A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy with or without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-407)                                                                       |
| R1306             | RTOG     | NCT01822496  | Lung- Non-Small Cell Lung Cancer | A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)                                                                                                                                                                            |
| S1400             | SWOG-L   | NCT02154490  | Lung- Non-Small Cell Lung Cancer | A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer                                                                                                                                                                                                                 |
| 30610             | CALGB    | NCT00632853  | Lung- Small Cell Lung Cancer     | Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin or Carboplatin and Etoposide                                                                                                                                        |
| EA6134            | ECOG-A   | NCT02224781  | Melanoma                         | A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma                                                          |
| EAQ152            | ECOG-A   | NCT02823652  | Multiple Disease Sites           | COMET - Communication and Education in Tumor Profiling: A Randomized Study of Pre-Disclosure Genetic Education v. Usual Care in Tumor Profiling for Advanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential Germline Mutations Identified on Tumor Profiling |
| EAY131            | ECOG-A   | NCT02465060  | Multiple Disease Sites           | Molecular Analysis for Therapy Choice (MATCH)                                                                                                                                                                                                                                                       |
| A061202           | ALLIANCE | NCT 02004275 | Multiple Myeloma                 | A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients With Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor-Based Therapy                                                                                              |
| E1A11             | ECOG     | NCT01863550  | Multiple Myeloma                 | Randomized Phase III Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma                                    |

**HSHS St. Vincent Hospital Regional Cancer Center –Adult Active Study List**

| Protocol        | Sponsor | NCT Number  | Disease Site                   | Title                                                                                                                                                                                                                                                                          |
|-----------------|---------|-------------|--------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| NSMM-5001       | DRUG CO | NCT02761187 | Multiple Myeloma               | A global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients - the INSIGHT-MM study                                                                                                           |
| S1211           | SWOG-L  | NCT01668719 | Multiple Myeloma               | A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)                                                                         |
| G0225           | GOG     | NCT00719303 | Ovarian                        | Can Diet and Physical Activity Modulate Ovarian or Primary Peritoneal Cancer Progression-Free Survival                                                                                                                                                                         |
| GY005           | NRG     | NCT02502266 | Ovarian                        | A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) |
| 0848            | RTOG    | NCT01013649 | Pancreas                       | A Phase II-R and A Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (PhIII) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma                                                                                             |
| 0924            | RTOG    | NCT01368588 | Prostate                       | Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial                                                                             |
| 39039039STM4001 | ACCRU   | NCT02555878 | Symptom/Side Effect Management | Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism                                                                                              |
| AFT-28          | AFT     | NCT02744092 | Symptom/Side Effect Management | Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS TRIAL)                                                                                                                                                 |
| 0238            | GOG     | NCT00492778 | Uterine-Endometrial            | A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus                                                                                                                |

**HSHS St. Vincent Hospital Regional Cancer Center –Adult Active Study List**

| Protocol | Sponsor | NCT Number  | Disease Site        | Title                                                                                                                                                                                                                |
|----------|---------|-------------|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| G0286B   | GOG     | NCT02065687 | Uterine-Endometrial | A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer |